About ALEVIAN, INC.
Alevian is a biotechnology company focused on developing regenerative therapeutics targeting neurological and aging-related diseases through the modulation of the GDF11 signaling pathway. Their lead candidate, ALE-001, is in clinical trials for acute ischemic stroke and preclinical stages for other indications.
Development of regenerative therapeutics targeting molecular cascades post-neurological injuryEngineering of recombinant GDF11 (ALE-001) to reactivate repair mechanismsAnti-inflammatory, neurogenic, angiogenic, stem-cell driven, and neuroprotective therapeutic propertiesPipeline spanning acute ischemic stroke, intracerebral hemorrhage, traumatic brain injury, chronic stroke, and metabolic age-related disease
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to ALEVIAN, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.